ArticleDiscover oncology2025
Cutting-edge dynamics and research hotspots on boswellic acid in cancer: a bibliometrics analysis from 1994 to 2024.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundRecent studies have highlighted the potential of boswellic acid as a promising therapeutic option in cancer treatment. Despite its growing relevance, there has been a lack of bibliometric analysis exploring the relationship between boswellic acid and cancer. The primary objective of this study was to provide a comprehensive overview of the research landscape, knowledge structure, and emerging trends surrounding boswellic acid and its potential use in oncology.
methodWe conducted a search in the Web of Science Core Collection (WoSCC) database for publications related to boswellic acid and cancer from 1994 to 2024. Bibliometric analysis was performed using tools such as VOSviewer, CiteSpace, and the R package "bibliometrix" to visualize and interpret the data.
resultsThe analysis included 332 publications from 49 different countries, with India and China leading in research output. The number of annual publications on boswellic acid and cancer has steadily increased since 2015. The University of Nizwa was identified as the leading institution contributing to this field. The European Journal of Medicinal Chemistry emerged as the most popular journal for publishing articles on this topic, while Planta Medica and Cancer Research received the highest citation counts. The author with the highest number of publications was Al-Harrasi Ahmed, and the most frequently co-cited researcher was Jian-Jun Liu. Emerging research hotspots include key terms such as "phytochemicals", "pharmacokinetics", and "bioavailability".
conclusionThis bibliometric analysis provides valuable insights into the current state of research on boswellic acid in cancer treatment. It serves as a useful resource for researchers and scholars seeking to explore the evolving landscape of boswellic acid's role in oncology, highlighting that "phytochemicals", "pharmacokinetics", and "bioavailability" might be the key research directions and trends of boswellic acid in cancer research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.